EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Vlado Perkovic, Hernán Trimarchi, Vladimir Tesar, Richard Lafayette, Muh Geot Wong, Jonathan Barratt, Yusuke Suzuki, Adrian Liew, Hong Zhang, Kevin Carroll, Vivekanand Jha iD, Alejandra Quevedo und 13 weitere

New England Journal of Medicine · 12.02.2026 · 394 (7) · 635-646

DOI: 10.1056/nejmoa2512133 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.02.2026. Verfasst von Vlado Perkovic und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of New South Wales, Sydney. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Glomerulonephritis, IGA, Hematuria, Proteinuria. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Otsuka Pharmaceutical Development & Commercialization, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGlomerulonephritis, IGAHematuriaProteinuriaTumor Necrosis Factor Ligand Superfamily Member 13AdultFemaleHumansMaleMiddle AgedYoung AdultCreatinineDouble-Blind MethodGlomerular Filtration RateImmunoglobulin AInjections, SubcutaneousAdolescentAgedAged, 80 and overTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedCreatinineImmunoglobulin ATumor Necrosis Factor Ligand Superfamily Member 13

Autor:innen und Institutionen

  • University of New South Wales, Sydney.
  • Hospital Británico, Buenos Aires.
  • Charles University, Prague, Czech Republic.
  • Stanford University Medical Center, Stanford, CA.
  • Concord Repatriation General Hospital, Concord, NSW, Australia.
  • University of Leicester, Leicester, United Kingdom.

ORCID-Profile: Vivekanand Jha

Förderung

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

Zitieren

APA

Perkovic, V., Trimarchi, H., Tesar, V., Lafayette, R., Wong, M. G., Barratt, J., Suzuki, Y., Liew, A., Zhang, H., Carroll, K., Jha, V., Quevedo, A., Han, S. H., Praga, M., Chacko, B., Sahay, M., Cheung, C. K., Kooienga, L., Walsh, M., …, & VISIONARY Trial Investigators Group (2026). Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial. New England Journal of Medicine, 394(7), 635-646. https://doi.org/10.1056/nejmoa2512133

Vancouver

Perkovic V, Trimarchi H, Tesar V, Lafayette R, Wong MG, Barratt J, et al. Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial. New England Journal of Medicine. 2026;394(7):635-646. doi:10.1056/nejmoa2512133

BibTeX
@article{Perkovic2026,
  author = {Perkovic, Vlado and Trimarchi, Hernán and Tesar, Vladimir and Lafayette, Richard and Wong, Muh Geot and Barratt, Jonathan and Suzuki, Yusuke and Liew, Adrian and Zhang, Hong and Carroll, Kevin and Jha, Vivekanand and Quevedo, Alejandra and Han, Seung Hyeok and Praga, Manuel and Chacko, Bobby and Sahay, Manisha and Cheung, Chee Kay and Kooienga, Laura and Walsh, Michael and Xia, Jing and Fajardo, Cecile and Shah, Lokesh and Hafkin, Jeffrey and Rizk, Dana V and VISIONARY Trial Investigators Group, VISIONARY Trial Investigators Group},
  title = {Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {7},
  pages = {635--646},
  doi = {10.1056/nejmoa2512133}
}
Kostenlos starten →